SCHEMBL1750474

SCHEMBL1750474

NC(=O)[N]C(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.54
MAPT P10636 3/20 0.54
CYP2C19 P33261 2/20 0.54
TSHR P16473 2/20 0.54
CYP3A4 P08684 2/20 0.54
BLM P54132 2/20 0.54
POLB P06746 1/20 0.54
PARP1 P09874 1/20 0.54
RECQL P46063 1/20 0.54
PMP22 Q01453 1/20 0.54
HSD17B10 Q99714 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
GAA P10253 2/20 0.48
CYP1A2 P05177 1/20 0.47
ALDH1A1 P00352 4/20 0.46
CES1 P23141 3/20 0.46
CES2 O00748 2/20 0.46
DAO P14920 1/20 0.46
NAPRT Q6XQN6 1/20 0.46
MAPK1 P28482 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL543877 0.85 CES1 (0.55) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL2880519 0.82 MAPT (0.50) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL7365656 0.82 CYP2C19 (0.50) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL3784819 0.80 CES1 (0.50) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL9678142 0.79 CYP2C19 (0.52) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL7778378 0.77 ALDH1A1 (0.50) TDP1MAPTPOLBGAAALDH1A1
SCHEMBL828587 0.76 TPH1 (0.55) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL3035866 0.76 CES2 (0.50) TDP1MAPTCYP2C19TSHRCYP3A4
SCHEMBL732449 0.75 TDP1 (0.52) TDP1MAPTCYP2C19TSHRCYP3A4
Hydrochloric Acid SCHEMBL27296270 0.74 TPH1 (0.53) TDP1MAPTCYP2C19TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-8703935-B2 Method of producing a metal phthalocyanine compound, and method of producing a phthalocyanine compound and an analogue thereof FUJIFILM CORPORATION (JP) 2014-04-22 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed
US-20130012697-A1 METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF FUJIFILM CORPORATION (JP) 2013-01-10 US disclosed
US-8299240-B2 Method of producing a metal phthalocyanine compound, and method of producing a phthalocyanine compound and an analogue thereof FUJIFILM CORPORATION (JP) 2012-10-30 US disclosed
EP-1940967-B1 METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF FUJIFILM CORP (JP) 2012-10-17 EP disclosed
US-20090247742-A1 METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF FUJIFILM CORPORATION (JP) 2009-10-01 US disclosed
EP-1984454-A1 METHOD OF MANUFACTURING PHTHALOCYANINE COMPOUND Fujifilm Corporation (JP) 2008-10-29 EP disclosed
EP-1940967-A1 METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF FUJIFILM Corporation (JP) 2008-07-09 EP disclosed
WO-2007086537-A1 METHOD OF MANUFACTURING PHTHALOCYANINE COMPOUND FUJIFILM CORPORATION (JP) 2007-08-02 WO disclosed
WO-2007037039-A1 METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF FUJIFILM CORPORATION (JP) 2007-04-05 WO disclosed
US-4341776-A BACTERICIDES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1982-07-27 US disclosed
US-4328224-A ANTIBIOTICS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1982-05-04 US disclosed
US-4301161-A BACTERICIDES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1981-11-17 US disclosed
US-4298605-A ANTIBIOTICS, BACTERICIDES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1981-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 TDP1 649/4885MAPT 2360/4885CYP2C19 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.